Holen Sie sich die Stockscreener-App
4.72
3.74%
0.17
Schlusskurs vom Vortag:
$4.55
Offen:
$4.5665
24-Stunden-Volumen:
2,895
Relative Volume:
0.02
Marktkapitalisierung:
$2.74M
Einnahmen:
$856.00K
Nettoeinkommen (Verlust:
$-12.56M
KGV:
-0.0204
EPS:
-231.4926
Netto-Cashflow:
$-4.14M
1W Leistung:
-9.40%
1M Leistung:
-19.32%
6M Leistung:
+33.33%
1J Leistung:
-90.67%
1-Tages-Spanne:
$4.50
$4.90
1-Wochen-Bereich:
$4.50
$5.21
52-Wochen-Spanne:
$2.98
$48.33
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
4.72 | 3.03M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
SciSparc Files June 30, 2026 Interim Results on Form 6-K - TipRanks
Net loss narrows to $6.05M, but SciSparc (SPRC) raises substantial doubt about continuing operations. - Stock Titan
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
Can SciSparc (NASDAQ:SPRC) Hold Today’s Attention? - kalkinemedia.com
SPRC Stock Price, Quote & Chart - ChartMill
SciSparc’s NeuroThera Expands U.S. Patent Portfolio for Psychedelic-PEA Therapies with Clearmind - TipRanks
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome - OTC Markets
SciSparc Awarded Three Patents For Its Novel Compounds and Methods - OTC Markets
LSD, ketamine and ibogaine feature in patent applications highlighted by SciSparc (SPRC). - Stock Titan
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance Singapore
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
SciSparc: Subsidiary NeuroThera Highlights Enhancement of - GlobeNewswire
Scisparc Ltd (SPRC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial - TipRanks
Tourette drug cut tics 21% in study as SciSparc (SPRC) advances trials - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - The Manila Times
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - marketscreener.com
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - The Manila Times
26 children have joined SciSparc’s two-compound autism treatment trial - Stock Titan
Neurothera Labs Inc. Announces Share Consolidation - TradingView
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com South Africa
SciSparc appoints AI professor to advisory board - Investing.com
Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026 - marketscreener.com
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board - Yahoo Finance
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionIV Crush Alert - vinanet.vn
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com Canada
SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind - Stock Titan
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy - TipRanks
SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo - Stock Titan
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - The Manila Times
SciSparc Subsidiary NeuroThera Receives Japanese Patent for 4-Aminophenol Combination Therapy - Quiver Quantitative
Japanese patent covers SciSparc subsidiary’s pain and fever combo - Stock Titan
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - TradingView
SciSparc (SPRC) Slips 0.87% to $6.87 as Biotech Stock Holds Above Key SupportTrend Continuation Trade - dars.gov.et
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Finanzdaten der Scisparc Ltd-Aktie (SPRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Scisparc Ltd-Aktie (SPRC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shrem Itschak | Director |
Jun 01 '26 |
Sale |
10.00 |
462 |
4,620 |
10,596 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):